Lin Bioscience and Columbia Technology Ventures announced that Lin Bioscience has licensed the intellectual property portfolio and development program for a promising first-in-class medication intended to slow or halt the progression of atrophic "Dry" Age-Related Macular Degeneration (AMD).
Fortress Biotech, Inc. announced the formation of a new subsidiary company, Caelum Biosciences, Inc., to advance the development of CAEL‐ 101 (11‐1F4) for the treatment of amyloid light chain (“AL”) amyloidosis.
Mannheim/Wetzlar, Germany. Leica Microsystems CMS GmbH has entered into an exclusive, worldwide licensing agreement with Columbia University in New York to commercialize SCAPE microscopy for Life Science applications.
Balance is an essential component of daily life, something many of us take for granted. But not everyone can. In the United States alone, there are about 300,000 people living with spinal cord injury (SCI) and some 12,000 new SCI cases each year, most of them young adults, 80% of them men.
Seventy-five percent of patients with moderate to severe alopecia areata—an autoimmune disease that causes patchy, and less frequently, total hair loss—had significant hair regrowth after treatment with ruxolitinib, reported researchers from Columbia University Medical Center (CUMC).